YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hype PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ardelyx, Inc. ARDX is a biopharmaceutical company developing medicines for unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been…
3 Healthcare Stocks That Concern Us Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising…
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks Looking back on branded pharmaceuticals stocks' Q2 earnings, we examine this quarter's best and worst performers, including Merck (NYSE:MRK) and…
3 Value Stocks That Fall Short Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are usually…
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky The past year hasn't been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they're witnessing fire…
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to…
Collegium Pharmaceutical, Inc. STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often m…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Confere…
Collegium Pharmaceutical, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick…
Key Points Interested in Collegium Pharmaceutical, Inc.? Here are five stocks we like better. Second-quarter revenue rose 6% to $199.9 million, driven by strong growth in JORNAY PM and the newly acquired AZSTARYS, which helped offset decli…
– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM®Quarterly Net Revenue of $46.1…
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago. These figures are adjusted for non-recu…
1 Cash-Producing Stock Worth Investigating and 2 We Ignore A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are crea…
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1 Let's dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Loo…
(RTTNews) - Collegium Pharmaceutical, Inc. (COLL), which develops and commercialises medicines for pain management, announced plans to relocate its corporate headquarters to One Lincoln in Downtown Boston in the first quarter of 2027. The…
1 Healthcare Stock with Competitive Advantages and 2 We Question Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial performance but a…
Tech stocks have been suffering over the past few weeks, as investors continue to rotate out of the artificial intelligence (AI)-focused tech and semiconductor stocks due to growing concerns over their sustainability. Despite a solid first…
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have…
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Concrete Pumping Holdings (BBCP): This company, which provides concrete pumping services and concrete waste management services primarily in U.S. and U.K, has seen th…
1 Mooning Stock to Own for Decades and 2 That Underwhelm Great things are happening to the stocks in this article. They're all outperforming the market over the last month because of positive catalysts such as a new product line, construct…
2 Profitable Stocks to Keep an Eye On and 1 We Brush Off While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said,…
Shares of Collegium Pharmaceutical COLL have gained around 12% over the past three months, driven by growing investor confidence in the company's expanding commercial portfolio, durable revenue base and long-term growth strategy. Jornay PM…
Neurocrine Biosciences NBIX) has quietly become one of biotech's strongest earnings stories, combining impressive commercial execution with a rapidly improving profit outlook. While many biotechnology companies remain years away from consi…
Neurocrine Biosciences NBIX) has quietly become one of biotech's strongest earnings stories, combining impressive commercial execution with a rapidly improving profit outlook. While many biotechnology companies remain years away from consi…
3 of Wall Street's Favorite Stocks We Approach with Caution The stocks in this article have caught Wall Street's attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain…
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data from…
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q1, starting with Bristol-Myers Squibb (NYSE:BMY). Looking ahead…
Collegium Pharmaceutical Inc (NASDAQ:COLL) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to gain 57% over the next 12 months.Interested in Collegium Pharma…
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022. Th…
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. Looking ahead, the branded pharmaceutical i…
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies,…
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped…
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 – – Co…
This article first appeared on GuruFocus. Insights into John Hussman (Trades, Portfolio)'s Strategic Moves in Q1 2026 Warning! GuruFocus has detected 4 Warning Signs with CORT. Is CORT fairly valued? Test your thesis with our free DCF calc…
Collegium Pharmaceutical, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Portfolio Evolution Performance in Q1 was characterized by a 9% increase in total net product revenue, driven by robust 36% growth in JORNAY PM a…